HOME > TOP STORIES
TOP STORIES
-
BUSINESS Keio Upstart, Novo Nordisk Ink Global Deal on iPSC-Based Heart Therapy
June 2, 2021
-
REGULATORY Blue Letter Issued to OA Drug Joyclu after Anaphylaxis Reports
June 2, 2021
-
BUSINESS SGLT2 Inhibitors Again Poised for Double-Digit Growth in FY2021; Forxiga Overtakes Jardiance in April
June 1, 2021
-
COMMENTARY Battle Looming over 2% Adjustment Rate as New Honebuto Paper Nears Completion
June 1, 2021
-
BUSINESS Ayumi Curbs Enbrel Biosimilar Shipments in Fallout from Indian API Supply Disruption
June 1, 2021
-
BUSINESS Pfizer Vaccine Now OK’ed for Adolescents, 1-Month Storage in Refrigerators
June 1, 2021
-
ORGANIZATION Experts Eye Macroeconomic Indexing of Drug Costs to Keep Innovation Afloat: INES Proposal
May 31, 2021
-
BUSINESS Yoshindo/Teijin Halt Enbrel Shipments as COVID-19 Stalls Indian API Supplies
May 31, 2021
-
REGULATORY Panel OK’s Pfizer Vaccine Use in Age 12-Plus, Longer Refrigerator Storage
May 31, 2021
-
ACADEMIA Hematologist Sees No Swelling Costs from 2 New CAR-T Contenders in Japan; Will Competition Drive Down Prices?
May 28, 2021
-
REGULATORY Japan Approves Rinvoq for Psoriasis, More Drugs for Label Expansions
May 28, 2021
-
BUSINESS Takeda Stepping Up Work to Improve Japanese Ecosystem for Rare Diseases
May 27, 2021
-
REGULATORY Govt Mulls New AMED Organ to Lead Strategic Funding for Vaccine Development
May 26, 2021
-
BUSINESS Sawai, Towa Post Domestic Sales Growth in FY2020, but Nichi-Iko Falters on GMP Violations: Jiho Tally
May 26, 2021
-
REGULATORY Japan Eyes Pfizer Vaccine Use in Younger People, Longer Refrigerator Storage
May 26, 2021
-
ORGANIZATION JPMA Positive on Use of Clinical Research Data in Submissions, but Wary of Funding Database
May 26, 2021
-
BUSINESS Flawed Stability Tests Found for 31 Choseido-Manufactured Products, Recalls Hit 15
May 25, 2021
-
REGULATORY MHLW Panel Backs Japan’s 1st Oncolytic Virus for Conditional Approval
May 25, 2021
-
BUSINESS Novartis Aims to Become Leader in Japan MS Market with Kesimpta Rollout
May 25, 2021
-
ORGANIZATION Ken Suzuki Likely to Come Back as JPWA Chief after 2 Years
May 25, 2021
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
